|
1
|
Oh MY, Oh SB, Seoung HG, et al: Clinical
significance of standardized uptake value and maximum tumor
diameter in patients with primary extranodal diffuse large B cell
lymphoma. The Korean journal of hematology. 47:207–212.
2012.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kashyap R, Rai Mittal B, Manohar K, et al:
Extranodal manifestations of lymphoma on [(1)(8)F]FDG-PET/CT: a
pictorial essay. Cancer imaging : the official publication of the
International Cancer Imaging Society. 11:166–174. 2011.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Illerhaus G, Schorb E and Kasenda B: Novel
agents for primary central nervous system lymphoma: evidence and
perspectives. Blood. 132:681–688. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ferreri AJ: How I treat primary CNS
lymphoma. Blood. 118:510–522. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Shi Y, Han Y, Yang J, et al: Clinical
features and outcomes of diffuse large B-cell lymphoma based on
nodal or extranodal primary sites of origin: Analysis of 1,085 WHO
classified cases in a single institution in China. Chinese journal
of cancer research = Chung-kuo yen cheng yen chiu. 31:152–161.
2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ferreri AJ: Risk of CNS dissemination in
extranodal lymphomas. Lancet Oncol. 15(e159-169)2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Sabattini E, Bacci F, Sagramoso C and
Pileri SA: WHO classification of tumours of haematopoietic and
lymphoid tissues in 2008: an overview. Pathologica. 102:83–87.
2010.PubMed/NCBI
|
|
8
|
Hoang-Xuan K, Bessell E, Bromberg J, et
al: Diagnosis and treatment of primary CNS lymphoma in
immunocompetent patients: guidelines from the European Association
for Neuro-Oncology. Lancet Oncol. 16(e322-332)2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Cesana C, Klersy C, Scarpati B, et al:
Flow cytometry and cytomorphology evaluation of hematologic
malignancy in cerebrospinal fluids: comparison with retrospective
clinical outcome. Ann Hematol. 90:827–835. 2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Raja H, Salomao DR, Viswanatha DS and
Pulido JS: Prevalence Of Myd88 L265p Mutation In Histologically
Proven, Diffuse Large B-Cell Vitreoretinal Lymphoma. Retina.
36:624–628. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Araujo I and Coupland SE: Primary
Vitreoretinal Lymphoma -- A Review. Asia-Pacific journal of
ophthalmology. 6:283–289. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Shin SY, Lee ST, Kim HJ, et al: Usefulness
of Flow Cytometric Analysis for Detecting Leptomeningeal Diseases
in Non-Hodgkin Lymphoma. Annals of laboratory medicine. 36:209–214.
2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Liu L, Cao F, Wang S, Zhou J, Yang G and
Wang C: Detection of malignant B lymphocytes by PCR clonality assay
using direct lysis of cerebrospinal fluid and low volume specimens.
International journal of laboratory hematology. 37:165–173.
2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Taniguchi K, Takata K, Chuang SS, et al:
Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse
Large B-Cell Lymphoma. Am J Surg Pathol. 40:324–334.
2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Zhou Y, Liu W, Xu Z, et al: Analysis of
Genomic Alteration in Primary Central Nervous System Lymphoma and
the Expression of Some Related Genes. Neoplasia. 20:1059–1069.
2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hiemcke-Jiwa LS, Minnema MC, Radersma-van
Loon JH, et al: The use of droplet digital PCR in liquid biopsies:
A highly sensitive technique for MYD88 p.(L265P) detection in
cerebrospinal fluid. Hematol. Oncol. 36:429–435. 2018.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Besson C, Goubar A, Gabarre J, et al:
Changes in AIDS-related lymphoma since the era of highly active
antiretroviral therapy. Blood. 98:2339–2344. 2001.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Postel M, Roosen A, Laurent-Puig P, Taly V
and Wang-Renault SF: Droplet-based digital PCR and next generation
sequencing for monitoring circulating tumor DNA: a cancer
diagnostic perspective. Expert review of molecular diagnostics.
18:7–17. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Olson JE, Janney CA, Rao RD, et al: The
continuing increase in the incidence of primary central nervous
system non-Hodgkin lymphoma: a surveillance, epidemiology, and end
results analysis. Cancer. 95:1504–1510. 2002.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Shiels MS, Pfeiffer RM, Besson C, et al:
Trends in primary central nervous system lymphoma incidence and
survival in the U.S. Br J Haematol. 174:417–424. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Low S, Han CH and Batchelor TT: Primary
central nervous system lymphoma. Therapeutic advances in
neurological disorders. 11(1756286418793562)2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yamanaka R, Morii K, Shinbo Y, et al: Late
relapse of primary central nervous system lymphoma. Leuk Lymphoma.
58:475–477. 2017. View Article : Google Scholar
|
|
24
|
Perkins A and Liu G: Primary Brain Tumors
in Adults: Diagnosis and Treatment. Am. Fam. Physician. 93:211–217.
2016.PubMed/NCBI
|
|
25
|
Dubois S, Viailly PJ, Bohers E, et al:
Biological and Clinical Relevance of Associated Genomic Alterations
in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma:
Analysis of 361 Cases. Clin Cancer Res. 23:2232–2244.
2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Xu Y, Li J, Ouyang J, et al: Prognostic
relevance of protein expression, clinical factors, and MYD88
mutation in primary bone lymphoma. Oncotarget. 8:65609–65619.
2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ansell SM, Hodge LS, Secreto FJ, et al:
Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in
non-Hodgkin lymphoma. Blood cancer journal. 4(e183)2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wenzl K, Manske MK, Sarangi V, et al: Loss
of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin
lymphoma. Blood cancer journal. 8(97)2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kraan W, Horlings HM, van Keimpema M, et
al: High prevalence of oncogenic MYD88 and CD79B mutations in
diffuse large B-cell lymphomas presenting at immune-privileged
sites. Blood cancer journal. 3(e139)2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kraan W, van Keimpema M, Horlings HM, et
al: High prevalence of oncogenic MYD88 and CD79B mutations in
primary testicular diffuse large B-cell lymphoma. Leukemia.
28:719–720. 2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yamada S, Ishida Y, Matsuno A and Yamazaki
K: Primary diffuse large B-cell lymphomas of central nervous system
exhibit remarkably high prevalence of oncogenic MYD88 and CD79B
mutations. Leuk Lymphoma. 56:2141–2145. 2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ngo VN, Young RM, Schmitz R, et al:
Oncogenically active MYD88 mutations in human lymphoma. Nature.
470:115–119. 2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Fontanilles M, Marguet F, Bohers E, et al:
Non-invasive detection of somatic mutations using next-generation
sequencing in primary central nervous system lymphoma. Oncotarget.
8:48157–48168. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Drandi D, Genuardi E, Dogliotti I, et al:
Highly sensitive MYD88(L265P) mutation detection by droplet digital
polymerase chain reaction in Waldenstrom macroglobulinemia.
Haematologica. 103:1029–1037. 2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zorofchian S, Lu G, Zhu JJ, et al:
Detection of the MYD88 p.L265P Mutation in the CSF of a Patient
With Secondary Central Nervous System Lymphoma. Front Oncol.
8(382)2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Hiemcke-Jiwa LS, Leguit RJ, Snijders TJ,
et al: Molecular analysis in liquid biopsies for diagnostics of
primary central nervous system lymphoma: Review of literature and
future opportunities. Crit Rev Oncol Hematol. 127:56–65.
2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Hattori K, Sakata-Yanagimoto M, Suehara Y,
et al: Clinical significance of disease-specific MYD88 mutations in
circulating DNA in primary central nervous system lymphoma. Cancer
Sci. 109:225–230. 2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zorofchian S, El-Achi H, Yan Y, Esquenazi
Y and Ballester LY: Characterization of genomic alterations in
primary central nervous system lymphomas. J Neurooncol.
140:509–517. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Gonzalez-Aguilar A, Idbaih A, Boisselier
B, et al: Recurrent mutations of MYD88 and TBL1XR1 in primary
central nervous system lymphomas. Clin Cancer Res. 18:5203–5211.
2012.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Fukumura K, Kawazu M, Kojima S, et al:
Genomic characterization of primary central nervous system
lymphoma. Acta Neuropathol. 131:865–875. 2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Glass S, Phan A, Williams JN, Flowers CR
and Koff JL: Integrating understanding of epidemiology and genomics
in B-cell non-Hodgkin lymphoma as a pathway to novel management
strategies. Discov Med. 21:181–188. 2016.PubMed/NCBI
|
|
42
|
Ding PN, Becker T, Bray V, et al: Plasma
next generation sequencing and droplet digital PCR-based detection
of epidermal growth factor receptor (EGFR) mutations in patients
with advanced lung cancer treated with subsequent-line osimertinib.
Thoracic cancer. 10:1879–1884. 2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Hiemcke-Jiwa LS, Leguit RJ, Snijders TJ,
et al: MYD88 p.(L265P) detection on cell-free DNA in liquid
biopsies of patients with primary central nervous system lymphoma.
Br J Haematol. 185:974–977. 2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Takhar JS, Doan TA and Gonzales JA:
Primary vitreoretinal lymphoma: empowering our clinical suspicion.
Curr. Opin. Ophthalmol. 30:491–499. 2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Lai J, Chen K, Shi HM, et al: B-scan
ultrasound and cytology of the vitreous in primary central nervous
system lymphoma with vitreoretinal involvement. Int J Ophthalmol.
12:1001–1007. 2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Chan CC, Rubenstein JL, Coupland SE, et
al: Primary vitreoretinal lymphoma: a report from an International
Primary Central Nervous System Lymphoma Collaborative Group
symposium. Oncologist. 16:1589–1599. 2011.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Morell AA, Shah AH, Cavallo C, et al:
Diagnosis of primary central nervous system lymphoma: a systematic
review of the utility of CSF screening and the role of early brain
biopsy. Neuro-oncology practice. 6:415–423. 2019.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Kopinska AJ, Helbig G, Koclega A and
Kyrcz-Krzemien S: Bing-Neel Syndrome with Detectable MYD88 L265P
Gene Mutation as a Late Relapse Following Autologous Hematopoietic
Stem Cell Transplantation for Waldenstrom's Macroglobulinemia.
Turkish journal of haematology: official journal of Turkish Society
of Haematology. 34:186–187. 2017.PubMed/NCBI View Article : Google Scholar
|
